Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
GIM-531 by Georgiamune for Metastatic Melanoma: Likelihood of Approval
GIM-531 is under clinical development by Georgiamune and currently in Phase II for Metastatic Melanoma. According to GlobalData, Phase II...
Data Insights
GIM-531 by Georgiamune for Solid Tumor: Likelihood of Approval
GIM-531 is under clinical development by Georgiamune and currently in Phase II for Solid Tumor. According to GlobalData, Phase II...